HALO Halozymedata gap · 92% coverage
Health Care · Biotechnology · close $121.84 (2026-10-16) · latest quarter in EDGAR: 2026-06-30
Halozyme (HALO) has a ThetaGrade House Rating of 57/100 (grade C), ranking #14 of 150 in Health Care. Its strongest pillars are cash flow (85) and growth (61); its weakest is valuation (34). Data gap: 2 factors without usable data, so 92% of the method weight is covered. TTM revenue growth is 41.2% and operating margin 35.9%.
Data as of .
Data gap
No usable data for: Consensus score (1–5), 90-day net rating shift. Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 92% of the full method weight is backed by data.
Analyst sentiment
weight 7.5% · no data · —| Consensus score (1–5) (0.0%)data gap | derived | — |
| 90-day net rating shift (0.0%)data gap | derived | — |
Growth
weight 30.83% (→33.3%) · 61| Revenue growth YoY (TTM) (13.3%) | 41.2% | 85 |
| EPS growth YoY (TTM) (13.3%) | -21.7% | 26 |
| Revenue acceleration (6.7%) | 5.4% | 83 |
Profitability
weight 18.5% (→20.0%) · 58| Operating margin (10.7%) | 35.9% | 94 |
| 4Q gross-margin change (9.3%) | -1.8% | 17 |
Balance sheet
weight 18.5% (→20.0%) · 44| Net debt / EBITDA (10.7%) | 3.26× | 23 |
| Current ratio (5.3%) | 2.71 | 52 |
| Interest coverage (4.0%) | 32.95× | 87 |
Cash flow
weight 12.33% (→13.3%) · 85| FCF margin (6.7%) | 46.2% | 98 |
| FCF yield (6.7%) | 4.7% | 72 |
Valuation
weight 12.33% (→13.3%) · 34| P/E (inverted) (6.7%) | 35.63× | 41 |
| EV/Sales (inverted) (6.7%) | 9.50× | 27 |
Technicals (EOD)
| RSI(14) | 70.3 |
| EMA 9 / 21 | 115.20 / 112.39 |
| 200-day SMA | 80.61 |
| Volume vs 20d avg | 0.71× |
| 20-day return | 11.1% |
Exit-rule monitor
- EXITRating break: House Rating below 60
Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Gross profit: Revenue − CostOfGoodsAndServicesSold · Operating income: OperatingIncomeLoss · Interest expense: InterestExpenseNonoperating · D&A: DepreciationDepletionAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close · P/E: EOD close ÷ SEC TTM EPS (EarningsPerShareDiluted).
Get rating changes like HALO's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is HALO's House Rating?
- HALO scores 57 out of 100 (grade C) as of 2026-10-16, ranking #14 of 150 Health Care stocks we cover.
- What do analysts say about HALO?
- We do not have enough analyst-sentiment data to score this stock.
- When does HALO report earnings next?
- We do not have a reliable estimate for HALO's next earnings date (irregular SEC filing history); a rough window is 2026-08-17 to 2027-01-18. Check the company's investor-relations page.
- Is HALO a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology